Bacac, Marina
F. Hoffmann-La Roche AG
4 papers on CoChatORCID 0000-0003-0581-9579
Most cited papers
- Verified
Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models
Herter, S., Herting, F., Mundigl, O., Waldhauer, I., Weinzierl, T., Fauti, T., Muth, G., Ziegler-Landesberger, D., Van Puijenbroek, E., Lang, S., et al. (2013) · Molecular Cancer Therapeutics
Lymphoma Diagnosis and TreatmentMonoclonal and Polyclonal Antibodies Research
Cited by 366
- Verified
Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines
Klein, C., Waldhauer, I., Nicolini, V. G., Freimoser-Grundschober, A., Nayak, T., Vugts, D. J., Dunn, C., Bolijn, M., Benz, J., Stihle, M., et al. (2017) · OncoImmunology
Monoclonal and Polyclonal Antibodies ResearchCancer Immunotherapy and Biomarkers
Cited by 281
- Verified
Human immunocompetent Organ-on-Chip platforms allow safety profiling of tumor-targeted T-cell bispecific antibodies
Kerns, S. J., Belgur, C., Petropolis, D., Kanellias, M., Barrile, R., Sam, J., Weinzierl, T., Fauti, T., Freimoser-Grundschober, A., Eckmann, J., et al. (2021) · eLife
3D Printing in Biomedical ResearchImmunotoxicology and immune responses
Cited by 82
- Verified
Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies
Leclercq-Cohen, G., Steinhoff, N., Albertí Servera, L., Nassiri, S., Danilin, S., Piccione, E., Yángüez, E., Hüsser, T., Herter, S., Schmeing, S., et al. (2023) · Clinical Cancer Research
CAR-T cell therapy researchMonoclonal and Polyclonal Antibodies Research
Cited by 65
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free